SAN DIEGO, April 2 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals,
Inc. (Amex: ANX), a biopharmaceutical research and development company
focused on commercializing proprietary product candidates for the treatment
of cancer and infectious diseases, announced today that Evan M. Levine,
chief executive officer, will present a corporate overview at the CIBC
World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference
on Thursday, April 12 at 9:10 a.m. Eastern Time. For more information on
the conference, visit http://conferences.cibcwm.com/biotech07/.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases. The Company
seeks to improve the performance and safety of existing treatments by
addressing significant problems such as drug metabolism, bioavailability,
excessive toxicity and treatment resistance. The Company's lead product
candidate, ANX-510 (CoFactor), is in Phase 3 and Phase 2b clinical trials
for the treatment of metastatic colorectal cancer, as well as in a Phase 2
clinical trial for the treatment of advanced breast cancer. More
information can be found on the Company's web site at
http://www.adventrx.com.
Forward Looking Statement
ADVENTRX cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other factors
that, if they do not materialize or prove to be accurate, could cause
ADVENTRX's results to differ materially from historical results or those
expressed or implied by such forward-looking statements. The potential
risks and uncertainties that could cause actual results to differ
materially include, but are not limited to: uncertainties inherent in the
drug development process; the timing and success of clinical trials; the
validity of research results; the receipt of necessary approvals from the
FDA and other regulatory agencies; and other risks and uncertainties more
fully described in ADVENTRX's press releases and public filings with the
Securities and Exchange Commission. ADVENTRX's public filings with the
Securities and Exchange Commission are available at http://www.sec.gov. ADVENTRX
does not intend to update any forward-looking statement, including as set
forth in this press release, to reflect events or circumstances arising
after the date on which it was made.
SOURCE ADVENTRX Pharmaceuticals, Inc.
 back to top
Related links:
http://www.adventrx.com
http://www.prnewswire.com/gh/cnoc/comp/920134.html
CONTACT:
Ioana C. Hone of ADVENTRX Pharmaceuticals,
Inc., +1-858-552-0866; or Amy Martini of WeissComm Partners,
+1-212-301-7223, for ADVENTRX Pharmaceuticals, Inc.
|
